DYRK2 and glioma: A multifactorial COX analysis of WHO grade IV gliomas combined with the patients’ preoperative KPS scores and postoperative radiotherapy showed that, similar to postoperative adjuvant radiotherapy, high expression of DYRK2 was an independent prognostic risk factor for WHO grade IV gliomas (HR = 1.55, 95% CI: 1.05–2.54, p = 0.003), and there was no correlation with the patients’ gender, age, etc. (p > 0.05) (Table 1).